Literature DB >> 16155280

Postmenopausal hormone therapy and body composition--a substudy of the estrogen plus progestin trial of the Women's Health Initiative.

Zhao Chen1, Tamsen Bassford, Sylvan B Green, Jane A Cauley, Rebecca D Jackson, Andrea Z LaCroix, Meryl Leboff, Marcia L Stefanick, Karen L Margolis.   

Abstract

BACKGROUND: It has been suggested that hormone therapy may help counter undesirable changes in body composition in older women.
OBJECTIVE: This study was designed to test whether estrogen plus progestin (E+P) therapy favorably affects age-related changes in body composition in postmenopausal women.
DESIGN: The substudy was composed of 835 women from the estrogen plus progestin trial of the Women's Health Initiative who were randomly assigned to receive either E+P therapy (n = 437) or placebo (n = 398). The women had a mean age of 63.1 y and, on average, were 13.8 y past menopause. More than 17% of the participants were from an ethnic minority. No significant differences in baseline body composition (measured with dual-energy X-ray absorptiometry) by intervention assignment were observed.
RESULTS: After 3 y of intervention, the women who received active E+P therapy lost less lean soft tissue mass (-0.04 kg) than did the women who received placebo (-0.44 kg; P = 0.001). Additionally, the women in the E+P group had less upper-body fat distribution than did the women in the placebo group (change in ratio of trunk to leg fat mass: -0.025 for the E+P group and 0.004 for the placebo group; P = 0.003). A sensitivity analysis, which was conducted on the women who took > or = 80% of the study medication during the intervention period, corroborated the findings from the intent-to-treat analysis.
CONCLUSIONS: A 3-y E+P intervention significantly reduced both the loss of lean soft tissue mass and the ratio of trunk to leg fat mass in postmenopausal women. However, the effect sizes were small, and whether these changes in body composition lead to significant health benefits remains to be confirmed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16155280     DOI: 10.1093/ajcn.82.3.651

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  44 in total

Review 1.  Regulation of Body Composition and Bioenergetics by Estrogens.

Authors:  Rachael E Van Pelt; Kathleen M Gavin; Wendy M Kohrt
Journal:  Endocrinol Metab Clin North Am       Date:  2015-06-20       Impact factor: 4.741

Review 2.  Management of obesity in the elderly: too much and too late?

Authors:  R L Kennedy; U Malabu; M Kazi; V Shahsidhar
Journal:  J Nutr Health Aging       Date:  2008-11       Impact factor: 4.075

Review 3.  A heartfelt message, estrogen replacement therapy: use it or lose it.

Authors:  Robert C Speth; Mikayla D'Ambra; Hong Ji; Kathryn Sandberg
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-09-14       Impact factor: 4.733

4.  Menopausal hormone therapy and new-onset diabetes in the French Etude Epidemiologique de Femmes de la Mutuelle Générale de l'Education Nationale (E3N) cohort.

Authors:  B de Lauzon-Guillain; A Fournier; A Fabre; N Simon; S Mesrine; M-C Boutron-Ruault; B Balkau; F Clavel-Chapelon
Journal:  Diabetologia       Date:  2009-07-23       Impact factor: 10.122

Review 5.  Validated treatments and therapeutics prospectives regarding pharmacological products for sarcopenia.

Authors:  G Onder; C Della Vedova; F Landi
Journal:  J Nutr Health Aging       Date:  2009-10       Impact factor: 4.075

6.  Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society.

Authors:  Wulf H Utian; David F Archer; Gloria A Bachmann; Christopher Gallagher; Francine n Grodstein; Julia R Heiman; Victor W Henderson; Howard N Hodis; Richard H Karas; Rogerio A Lobo; JoAnn E Manson; Robert L Reid; Peter J Schmidt; Cynthia A Stuenkel
Journal:  Menopause       Date:  2008 Jul-Aug       Impact factor: 2.953

7.  Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with body composition changes in women on aromatase inhibitors for ER (+) breast cancer.

Authors:  Nicola Napoli; Antonella Rastelli; Cynthia Ma; Georgia Colleluori; Swapna Vattikuti; Reina Armamento-Villareal
Journal:  Pharmacogenet Genomics       Date:  2015-08       Impact factor: 2.089

8.  Estrogen therapy and bone mineral density in African-American and Caucasian women.

Authors:  Susan L Eskridge; Deborah J Morton; Donna Kritz-Silverstein; Elizabeth Barrett-Connor; Deborah Wingard; Wilma Wooten
Journal:  Am J Epidemiol       Date:  2010-02-23       Impact factor: 4.897

9.  Changes in physical activity and body composition in postmenopausal women over time.

Authors:  Stacy T Sims; Jessica Kubo; Manisha Desai; Jennifer Bea; Jeannette M Beasley; Joann E Manson; Matthew Allison; Rebecca A Seguin; Zhao Chen; Yvonne L Michael; Shannon D Sullivan; Shirley Beresford; Marcia L Stefanick
Journal:  Med Sci Sports Exerc       Date:  2013-08       Impact factor: 5.411

10.  Hormone therapy improves femur geometry among ethnically diverse postmenopausal participants in the Women's Health Initiative hormone intervention trials.

Authors:  Zhao Chen; Thomas J Beck; Jane A Cauley; Cora E Lewis; Andrea LaCroix; Tamsen Bassford; Guanglin Wu; Duane Sherrill; Scott Going
Journal:  J Bone Miner Res       Date:  2008-12       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.